DK2427177T3 - Sammensætning til langvarig lægemiddelafgivelse omfattende geopolymerbindemiddel - Google Patents

Sammensætning til langvarig lægemiddelafgivelse omfattende geopolymerbindemiddel Download PDF

Info

Publication number
DK2427177T3
DK2427177T3 DK10718263.6T DK10718263T DK2427177T3 DK 2427177 T3 DK2427177 T3 DK 2427177T3 DK 10718263 T DK10718263 T DK 10718263T DK 2427177 T3 DK2427177 T3 DK 2427177T3
Authority
DK
Denmark
Prior art keywords
composition
api
release
ddss
fentanyl
Prior art date
Application number
DK10718263.6T
Other languages
English (en)
Inventor
Håkan Engqvist
Original Assignee
Emplicure Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emplicure Ab filed Critical Emplicure Ab
Application granted granted Critical
Publication of DK2427177T3 publication Critical patent/DK2427177T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (15)

1. Farmaceutisk sammensætning med langvarig frigivelse omfattende en farmaceutisk aktiv bestanddel, eller et farmaceutisk acceptabelt salt deraf, og et geopolymerbindemiddel.
2. Sammensætning ifølge krav 1, kendetegnet ved, at den farmaceutiske aktive bestanddel er kombineret med geopolymerbindemidlet under dannelse af dette bindemiddel.
3. Sammensætning ifølge krav 1 eller 2, hvor den farmaceutiske aktive bestanddel er et opioidanalgetikum.
4. Sammensætning ifølge krav 3, hvor opioidanalgetikummet er valgt blandt buprenorphin, alfentanil, sufentanil, remifentanil og fentanyl.
5. Sammensætning ifølge krav 4, hvor opioidanalgetikummet er fentanyl.
6. Sammensætning ifølge et af kravene 1 til 5, hvor sammensætningen er beregnet til topisk påføring.
7. Fremgangsmåde til fremstilling afen sammensætning ifølge etaf kravene 1 til 6, der omfatter omsætning af et aluminiumsilicat-prækursormateriale med en vandig alkalisk væske.
8. Fremgangsmåde ifølge krav 7, hvor omsætningen udføres under nærvær af en silicakilde, eller hvor den vandige alkaliske væske omfatter silicat.
9. Fremgangsmåde ifølge krav 7 eller 8, hvor aluminiumsilicat-prækursorma-terialet er metakaolin.
10. Fremgangsmåde ifølge et af kravene 7 til 9, hvor aluminiumsilicat-prækur-sormaterialet er i form af et pulver med en kornstørrelse under ca. 30 pm.
11. Fremgangsmåde ifølge et af kravene 7 til 10, hvor geopolymermaterialet dannes ved hærdning ved ca. 40° C.
12. Sammensætning ifølge et af kravene 1 til 6 til anvendelse som medicin.
13. Sammensætning ifølge et af kravene 3 til 6 til anvendelse ved smertebehandling.
14. Anvendelse afen sammensætning ifølge et af kravene 3 til 5 til fremstilling af et medikament til smertebehandling.
15. Tablet fremstillet ved en fremgangsmåde med at: (i) danne en pasta af en medicinsk sammensætning med langvarig frigivelse til dannelse afen medicinsk sammensætning, hvor den medicinske sammensætning med langvarig frigivelse fremstilles af: (a) en pulversammensætning omfattende mindst en aluminiumsilicatfase, hvor fasen eventuelt er valgt fra gruppen: kaolin, dickit, halloysit, nacrit, zeolit, illit, fortrinsvis dehydroxyleret zeolit, halloysit eller kaolin, og mest foretrukket me-takaolin; (b) en alkalisk væske på vandbasis; og (c) en medicinsk farmaceutisk aktiv bestanddel (API); (ii) granulere den medicinske sammensætning, og (iii) hærde granulatet og (iv) danne en tablet af den hærdede medicinske sammensætning.
DK10718263.6T 2009-05-08 2010-05-07 Sammensætning til langvarig lægemiddelafgivelse omfattende geopolymerbindemiddel DK2427177T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0900626 2009-05-08
SE1000117 2010-02-08
PCT/GB2010/000910 WO2010128300A1 (en) 2009-05-08 2010-05-07 Composition for sustained drug delivery comprising geopolymeric binder

Publications (1)

Publication Number Publication Date
DK2427177T3 true DK2427177T3 (da) 2018-06-18

Family

ID=42638663

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10718263.6T DK2427177T3 (da) 2009-05-08 2010-05-07 Sammensætning til langvarig lægemiddelafgivelse omfattende geopolymerbindemiddel

Country Status (15)

Country Link
US (2) US9486527B2 (da)
EP (1) EP2427177B1 (da)
JP (1) JP5691051B2 (da)
KR (1) KR101830080B1 (da)
CN (1) CN102421419B (da)
AU (1) AU2010244194B2 (da)
BR (1) BRPI1011412A8 (da)
CA (1) CA2761000C (da)
DK (1) DK2427177T3 (da)
EA (1) EA027618B1 (da)
ES (1) ES2673196T3 (da)
IL (1) IL215826A (da)
MX (1) MX2011011829A (da)
PL (1) PL2427177T3 (da)
WO (1) WO2010128300A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2427177B1 (en) * 2009-05-08 2018-03-28 Emplicure AB Composition for sustained drug delivery comprising geopolymeric binder
PL2493457T3 (pl) 2009-10-30 2018-01-31 Ix Biopharma Ltd Szybko rozpuszczalna stała postać dawkowana
UA102627C2 (uk) * 2012-03-20 2013-07-25 Общество С Ограниченной Ответственностью "Наномедтраст" Нанокомпозит оксид церію-алюмосилікатні трубки та спосіб його отримання
EP3583935A1 (en) 2012-04-25 2019-12-25 SPI Pharma, INC. Crystalline microspheres and the process for manufacturing the same
PL2872121T3 (pl) 2012-07-12 2019-02-28 SpecGx LLC Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania
WO2014078435A1 (en) 2012-11-14 2014-05-22 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide
US20140194328A1 (en) 2013-01-07 2014-07-10 Vince Alessi Thermoset ceramic compositions and a method of preparation therefor
CN109069769A (zh) * 2016-02-29 2018-12-21 埃姆普里居公司 用于蒸发和吸入活性剂的装置
CN105997907A (zh) * 2016-05-16 2016-10-12 胡小丽 高血压治疗药丸
CN105997915A (zh) * 2016-05-16 2016-10-12 张阳 一种高血压治疗用缓释片剂
CN105769798A (zh) * 2016-05-16 2016-07-20 张阳 一种高血压治疗药物的制备方法
KR102007278B1 (ko) 2017-01-19 2019-08-06 가톨릭대학교 산학협력단 바이러스 진단 및 치료를 위한 인지능 물질 및 이의 제조방법

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0391893B1 (en) 1983-11-14 1993-08-25 The University of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
GB2196252B (en) 1986-09-18 1990-10-17 London Pharmacy Innovation Gastric controlled-release dosage forms
IT1197316B (it) 1986-10-01 1988-11-30 Proter Spa Formulazione galenica ad uso orale di derivati della reina a lento rilascio per impiego terapeutico
JP2702953B2 (ja) 1988-01-30 1998-01-26 オリンパス光学工業株式会社 薬液含浸セラミックス
IT1216570B (it) 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
JPH01268104A (ja) * 1988-04-20 1989-10-25 Matsushita Electric Works Ltd チョークコイル
JPH0230988A (ja) 1988-07-20 1990-02-01 Toshiba Corp 宇宙軌道上発電プラント
JPH02268104A (ja) 1989-04-07 1990-11-01 Kanebo Ltd 抗菌性組成物
US5443812A (en) 1989-04-24 1995-08-22 Kanebo Ltd. Stabilized synthetic zeolite and a process for the preparation thereof
JPH07188000A (ja) 1993-12-27 1995-07-25 Bridgestone Corp 薬用被覆材
JPH0930988A (ja) 1995-07-21 1997-02-04 Sumitomo Osaka Cement Co Ltd 薬剤徐放性多孔質セラミックス成形体及びその製造方法
GB2307862A (en) 1995-12-05 1997-06-11 David Jehan Patch structures for transdermal therapy
WO1998023556A1 (fr) 1996-11-25 1998-06-04 Kabushiki Kaisya Advance Procede de production de ceramiques
US5902591A (en) 1997-04-03 1999-05-11 La Prairie Sa Stable topical cosmetic/pharmaceutical emulsion compositions containing ascorbic acid
US6503231B1 (en) 1998-06-10 2003-01-07 Georgia Tech Research Corporation Microneedle device for transport of molecules across tissue
US6123925A (en) * 1998-07-27 2000-09-26 Healthshield Technologies L.L.C. Antibiotic toothpaste
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US20030118641A1 (en) 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
AUPQ573300A0 (en) * 2000-02-21 2000-03-16 Australian Nuclear Science & Technology Organisation Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use
WO2001072663A2 (en) 2000-03-24 2001-10-04 Lyles Mark B High density porous materials
CZ301790B6 (cs) 2000-04-11 2010-06-23 Sankyo Company Limited Farmaceutický prípravek obsahující blokátor vápníku
US20020122828A1 (en) 2001-03-02 2002-09-05 Jun Liu Hybrid porous materials for controlled release
US6767557B2 (en) 2001-03-05 2004-07-27 Ortho-Mcneil Pharmaceutical, Inc. Taste masked pharmaceutical compositions
EP1429819B1 (en) 2001-09-24 2010-11-24 Boston Scientific Limited Optimized dosing for paclitaxel coated stents
PT1429802E (pt) 2001-09-28 2013-01-24 Tntgamble Inc Sistema de entrega para componente biológico
JP2005518354A (ja) 2001-11-19 2005-06-23 コントロール・デリバリー・システムズ・インコーポレイテッド コドラッグを含有する医薬組成物
JP2005526839A (ja) 2002-04-23 2005-09-08 アルザ・コーポレーシヨン 不正使用の可能性が低い経皮鎮痛薬システム
AU2003222691A1 (en) 2002-04-30 2003-11-17 Morteza Shirkhanzadeh Arrays of microneedles comprising porous calcium phosphate coating and bioactive agents
AU2003275311A1 (en) 2002-09-16 2004-04-30 Sung-Yun Kwon Solid micro-perforators and methods of use
SE524334C2 (sv) 2002-09-30 2004-07-27 Cerbio Tech Ab Värmegenererande biokompatibla keramiska material och förfarande för dess framställning
SE525236C2 (sv) 2002-10-31 2005-01-11 Cerbio Tech Ab Förfarande för framställning av strukturerade keramiska beläggningar och belagda anordningar framställda med detta förfarande
SE524494C2 (sv) 2002-12-31 2004-08-17 Doxa Ab Kemiskt bundna biomaterialelement med skräddarsydda egenskaper
AU2003273010A1 (en) 2003-10-15 2005-05-05 Ltt Bio-Pharma Co., Ltd. Composition containing retinoic acid nanoparticles coated with polyvalent metal inorganic salt
KR20060115398A (ko) 2003-10-29 2006-11-08 독사 악티에볼락 개선된 생체 재료의 초기 및 최종 특성을 위한 2단계시스템
US20050181049A1 (en) 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
NZ548216A (en) * 2003-12-31 2010-02-26 Cima Labs Inc Generally linear effervescent oral fentanyl dosage form and methods of administering
US7914813B2 (en) 2004-02-03 2011-03-29 Hisamitsu Pharmaceutical Co., Inc. Interface for transdermal drug administration device
US7315758B2 (en) 2004-06-03 2008-01-01 Lynntech, Inc. Transdermal delivery of therapeutic agent
WO2006000229A2 (en) 2004-06-28 2006-01-05 Lifecycle Pharma A/S Porous tablets as carriers for liquid formulations
CN101001610A (zh) 2004-07-13 2007-07-18 爱尔达纳米公司 防止药物转向的陶瓷结构
CA2573344A1 (en) * 2004-07-13 2006-02-16 Altairnano, Inc. Ceramic structures for controlled release of drugs
US7537590B2 (en) 2004-07-30 2009-05-26 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
WO2006023286A2 (en) 2004-08-19 2006-03-02 Alza Corporation Controlled release nanoparticle active agent formulation dosage forms and methods
US8535702B2 (en) 2005-02-01 2013-09-17 Boston Scientific Scimed, Inc. Medical devices having porous polymeric regions for controlled drug delivery and regulated biocompatibility
FR2881652B1 (fr) 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
WO2006096544A1 (en) 2005-03-04 2006-09-14 Altairnano, Inc. Ceramic structures for controlled release of biologically active substances
DE102005040429A1 (de) 2005-08-25 2007-03-01 Heraeus Kulzer Gmbh Wirkstofffreisetzungssystem und seine Verwendung
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
US7682445B2 (en) 2005-12-08 2010-03-23 Doxa Ab Powdered CBC system with improved reaction feature
US20090104286A1 (en) 2005-12-29 2009-04-23 Robert Basic Regulation of allergic reaction
US20070212414A1 (en) 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US20070248656A1 (en) * 2006-04-25 2007-10-25 Galer Bradley S Topical preparation dispensers and methods of using the same
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
DE102006028781A1 (de) 2006-06-23 2007-12-27 Robert Bosch Gmbh Verfahren zur Herstellung von porösen Mikronadeln und ihre Verwendung
US20080214987A1 (en) 2006-12-22 2008-09-04 Nanomed Devices, Inc. Microdevice And Method For Transdermal Delivery And Sampling Of Active Substances
WO2008105737A1 (en) 2007-03-01 2008-09-04 Doxa Ab Stable cement composition for orthopaedic and dental use
US8778377B2 (en) 2007-03-01 2014-07-15 Doxa Ab Drug implant carrier for drug delivery
EP2131878A4 (en) 2007-03-01 2012-12-26 Doxa Ab INJECTABLE CEMENT COMPOSITION FOR ORTHOPEDIC AND DENTAL PURPOSES
EP2139531A4 (en) * 2007-03-28 2013-01-09 Doxa Ab CARRIER FOR DRUG DISPENSING
CN101104080B (zh) * 2007-04-24 2011-06-22 深圳市鸿华投资有限公司 沸石止血敷料及其制备方法和用途
GB0709541D0 (en) 2007-05-17 2007-06-27 Jagotec Ag Pharmaceutical excipient
EP2100850A1 (en) 2008-03-11 2009-09-16 Stichting Voor De Technische Wetenschappen Microneedle array and a method for manufacturing microneedles
WO2010096704A2 (en) 2009-02-19 2010-08-26 Alex Garfield Bonner Porous interpenetrating polymer network
EP2427177B1 (en) * 2009-05-08 2018-03-28 Emplicure AB Composition for sustained drug delivery comprising geopolymeric binder
ES2658913T3 (es) * 2010-09-07 2018-03-12 Emplicure Ab Dispositivo de administración transdérmica de un fármaco

Also Published As

Publication number Publication date
JP2012526091A (ja) 2012-10-25
BRPI1011412A2 (pt) 2016-03-15
JP5691051B2 (ja) 2015-04-01
CN102421419B (zh) 2016-05-04
EA027618B1 (ru) 2017-08-31
BRPI1011412A8 (pt) 2018-01-02
KR101830080B1 (ko) 2018-02-21
CN102421419A (zh) 2012-04-18
CA2761000C (en) 2018-05-29
AU2010244194B2 (en) 2014-12-04
AU2010244194A1 (en) 2011-11-10
US20120252845A1 (en) 2012-10-04
IL215826A0 (en) 2012-01-31
PL2427177T3 (pl) 2018-09-28
EP2427177B1 (en) 2018-03-28
US10092652B2 (en) 2018-10-09
EA201101596A1 (ru) 2012-05-30
EP2427177A1 (en) 2012-03-14
US9486527B2 (en) 2016-11-08
ES2673196T3 (es) 2018-06-20
IL215826A (en) 2016-11-30
MX2011011829A (es) 2012-02-21
KR20120015344A (ko) 2012-02-21
WO2010128300A1 (en) 2010-11-11
US20170112932A1 (en) 2017-04-27
CA2761000A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
US10543203B2 (en) Abuse resistant formula
US10092652B2 (en) Composition for sustained drug delivery comprising geopolymeric binder
US10736838B2 (en) Transdermal drug administration device